Cardiovascular

Off-label use of recombinant activated factor VII increases risk of arterial events

Off-label use of recombinant activated factor VII (rFVIIa) increases the risk of arterial but not venous thromboembolic events, particularly in older patients, according to an analysis of randomized clinical trials in the New England Journal of Medicine. Read more here.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares